Pilar García‐Alfonso

Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer

Marwan Fakih, S. Gill, K. Sampat, David Chan et autres

us, au, cu, es, Gabon, it, ca (code pays fourni par la source)

Correction: Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study

Álvaro Rodríguez-Lescure, Javier Gállego, Pilar García‐Alfonso, Bartomeu Massutí et autres

es (code pays fourni par la source)

Supplementary Tables S1-S8 from Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study

Joana Vidal, Concepción Fernández‐Rodríguez, David Casadevall, Pilar García‐Alfonso et autres

Budget impact analysis of new drugs in oncology and haematology: Principles and practice

Javier Soto Alsar, José Luis Revuelta-Herrero, Cristina Villanueva‐Bueno, Carmen Cobos‐Lama et autres

es (code pays fourni par la source)

Clinical validation of liquid biopsy-RECIST (LB-RECIST) in metastatic colorectal cancer (mCRC) patients: findings from the PLATFORM-B study

Valentino Martelli, Joana Vidal, Joan Gibert, Concepción Fernández‐Rodríguez et autres

es (code pays fourni par la source)

Definition of lines of treatment in metastatic colorectal cancer: a Delphi consensus

Pilar García‐Alfonso, Julia Alcaide, Enrique Aranda, Elena Élez et autres

es (code pays fourni par la source)

Circulating hsa‐miR‐29c‐3p and VEGF‐A levels predict the response to FOLFIRI plus aflibercept in elderly metastatic colorectal cancer patients

Marta Toledano‐Fonseca, María Teresa Cano‐Osuna, Elena Élez, Javier Soto‐Alsar et autres

es, us (code pays fourni par la source)

Analysis of fruquintinib in patients with metastatic colorectal cancer who were enrolled in Spain: results from the global FRESCO-2 study

R. Garcia-Carbonero, E. Elez, Pilar García‐Alfonso, A. Cubillo Gracían et autres

es, us, it, gb (code pays fourni par la source)

Overall survival with fruquintinib versus placebo after adjusting for subsequent anticancer therapy in patients with refractory metastatic colorectal cancer in the FRESCO-2 study.

Sara Lonardi, Arvind Dasari, Josep Tabernero, Rocio García‐Carbonero et autres

it, us, es, jp, hu, fr, cz, au (code pays fourni par la source)

Associations of blood RNA biomarkers and circulating tumour cells in patients with previously untreated metastatic colorectal cancer

Manuel Valladares‐Ayerbes, Marta Toledano‐Fonseca, Begoña Graña, Paula Jiménez‐Fonseca et autres

es (code pays fourni par la source)

State of the art of the molecular hyperselection to guide treatment with anti-EGFR antibodies in RAS WT mCRC: implications for clinical practice and future perspectives

Pilar García‐Alfonso, Manuel Valladares‐Ayerbes, Andrés J. Muñoz Martín, Rocío Morales Herrero et autres

es, ca, us (code pays fourni par la source)

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2

Cathy Eng, Arvind Dasari, Sara Lonardi, Rocio García‐Carbonero et autres

us, it, es, jp, hu, fr, cz, au (code pays fourni par la source)